These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 36084200

  • 1. Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study.
    Morris SR, Jain S, Blumenthal J, Bolan R, Dubé MP, Henderson P, Corado K, Sun S, He F, Chow K, Burke L, Anderson PL, Moore DJ.
    J Acquir Immune Defic Syndr; 2022 Dec 15; 91(5):453-459. PubMed ID: 36084200
    [Abstract] [Full Text] [Related]

  • 2. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
    Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR.
    Clin Infect Dis; 2018 May 02; 66(10):1566-1572. PubMed ID: 29228144
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, Chinbunchorn T, Janyam S, Linjongrat D, Puthanakit T, CE-PID - TRC Adolescent Study Team.
    J Int AIDS Soc; 2020 Sep 02; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial.
    Kawichai S, Songtaweesin WN, Wongharn P, Phanuphak N, Cressey TR, Moonwong J, Vasinonta A, Saisaengjan C, Chinbunchorn T, Puthanakit T.
    JMIR Mhealth Uhealth; 2022 Apr 21; 10(4):e25561. PubMed ID: 35451976
    [Abstract] [Full Text] [Related]

  • 7. Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: A pilot randomized clinical trial.
    Moore DJ, Pasipanodya EC, Umlauf A, Rooney AS, Gouaux B, Depp CA, Atkinson JH, Montoya JL.
    Drug Alcohol Depend; 2018 Aug 01; 189():154-160. PubMed ID: 29958127
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators.
    Lancet HIV; 2015 Dec 01; 2(12):e512-9. PubMed ID: 26614965
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM).
    Lancet HIV; 2017 Nov 01; 4(11):e522-e528. PubMed ID: 28919303
    [Abstract] [Full Text] [Related]

  • 12. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
    Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD.
    PLoS One; 2017 Nov 01; 12(7):e0181607. PubMed ID: 28750059
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adherence to Daily Oral TDF/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study.
    Smith DK, Rawlings MK, Glick N, Mena L, Coleman M, Houlberg M, McCallister S, Wiener J.
    AIDS Behav; 2022 Feb 01; 26(2):350-360. PubMed ID: 34347198
    [Abstract] [Full Text] [Related]

  • 15. Individualized texting for adherence building (iTAB): improving antiretroviral dose timing among HIV-infected persons with co-occurring bipolar disorder.
    Moore DJ, Poquette A, Casaletto KB, Gouaux B, Montoya JL, Posada C, Rooney AS, Badiee J, Deutsch R, Letendre SL, Depp CA, Grant I, Atkinson JH, HIV Neurobehavioral Research Program (HNRP) Group.
    AIDS Behav; 2015 Mar 01; 19(3):459-71. PubMed ID: 25504449
    [Abstract] [Full Text] [Related]

  • 16. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
    Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, McConnell M, van der Straten A, Baeten JM, Duyver M, Mendel E, Naidoo K, Dallimore J, Wiesner L, Bekker LG.
    J Int AIDS Soc; 2020 Nov 01; 23(11):e25636. PubMed ID: 33247553
    [Abstract] [Full Text] [Related]

  • 17. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    Ibrahim ME, Castillo-Mancilla JR, Yager J, Brooks KM, Bushman L, Saba L, Kiser JJ, MaWhinney S, Anderson PL.
    AIDS Res Hum Retroviruses; 2021 Jun 01; 37(6):421-428. PubMed ID: 33191774
    [Abstract] [Full Text] [Related]

  • 18. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR, Podany AT, Havens JP, Bares SH, Dyavar SR, Gwon Y, Johnson TM, Amoura NJ, Fletcher CV, Scarsi KK.
    J Antimicrob Chemother; 2020 May 01; 75(5):1242-1249. PubMed ID: 32065631
    [Abstract] [Full Text] [Related]

  • 19. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.
    Antimicrob Agents Chemother; 2018 Jan 01; 62(1):. PubMed ID: 29038282
    [Abstract] [Full Text] [Related]

  • 20. PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014-2018, USA).
    Townes A, Pyra M, Smith DK, Babu AS, Williams T, Wiener J, Henny KD, Schneider J.
    AIDS Behav; 2023 Mar 01; 27(3):901-908. PubMed ID: 36094640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.